Cholestech begins US delivery of liver enzyme test:
This article was originally published in Clinica
Executive Summary
Hayward, California-based diagnostics developer Cholestech has begun shipping in the US its Aspartate Aminotransferase (AST) test for assessing damage to the liver due to drugs or certain diseases. The assay, the only CLIA-waivered one of its kind, runs on Cholestech's LDX system in conjunction with its other liver enzyme test, Alanine Aminotransferase (ALT). Nearly 200 million ALT and AST tests are ordered in the US each year, says Cholestech.
You may also be interested in...
US Q1 Consumer Health Earnings Preview: Label This One Historic And Challenging But Promising
US OTC drug and supplement firms’ reports of results for the first three months of 2024 began on April 19 with P&G. JP Morgan analysts say while “some retailers in the US in particular” are reducing consumer health inventories, for the overall sector they expect “a healthier balance of positive volume and lower pricing contribution.”
Keeping Track: Cancer Approvals From Lumisight Imaging To Adjuvant Alecensa
The US FDA’s approval of Lumicell’s optical imaging agent Lumisight makes a dozen novel approvals in 2024 for the Center for Drug Evaluation and Research.
Partisan Politics Returns To US FDA Congressional Oversight
The US FDA has stood out as an agency that tends to draw broad bipartisan support amid a generally rancorous and divided Congress. A House hearing, however, may be a sign that those days are over.